Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study
HER2-low status was not associated with prognosis or predictive value for CDK4/6i efficacy, supporting CDK4/6i + AI as the standard first-line therapy irrespective of HER2 expression level.
Authors
- Napa Parinyanitikul (ORCID: https://orcid.org/0000-0003-3701-5663)
- Archara Supavavej (ORCID: https://orcid.org/0000-0002-3270-5553)
- Concord Wongkraisri (ORCID: https://orcid.org/0000-0002-8819-4211)
- Suthinee Ithimakin (ORCID: https://orcid.org/0000-0002-4205-6112)
- Thitiya Dejthevaporn (ORCID: https://orcid.org/0000-0003-1808-7303)
- Sunee Neesanun (ORCID: https://orcid.org/0000-0002-8349-3730)
- Arunee Dechaphunkul (ORCID: https://orcid.org/0000-0002-0593-4385)
- Patrapim Sunpaweravong (ORCID: https://orcid.org/0000-0001-9787-270X)
- Thanate Dajsakdipon (ORCID: https://orcid.org/0000-0002-3474-3414)
- Thiti Susiriwatananont (ORCID: https://orcid.org/0000-0001-6916-3383)
Institutions
- Thai Red Cross Society (TH)
- Prince of Songkla University (TH)
- Siriraj Hospital (TH)
- Chulalongkorn University (TH)
- Mahidol University (TH)
- King Chulalongkorn Memorial Hospital (TH)
- Chulabhorn Hospital (TH)
- Ramathibodi Hospital (TH)
- Charoenkrung Pracharak Hospital (TH)
Publication Details
- Journal
- International Journal of Breast Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1155/ijbc/5597051
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52